Premium Nahrungsergänzungsmittel | artgerecht

Ubiquinol Biokinetics – Absorption and Body Distribution

Ubiquinol biokinetics describes how the body absorbs, distributes, metabolizes, and excretes the reduced form of Coenzyme Q10. Understanding these processes is key to optimizing supplementation efficacy.

Regular tips about health Regular tips about health

Things worth knowing about "Ubiquinol Biokinetics"

Ubiquinol biokinetics describes how the body absorbs, distributes, metabolizes, and excretes the reduced form of Coenzyme Q10. Understanding these processes is key to optimizing supplementation efficacy.

What is Ubiquinol Biokinetics?

Ubiquinol biokinetics refers to the pharmacokinetic properties of ubiquinol – the reduced, biologically active form of Coenzyme Q10 (CoQ10) – within the human body. Biokinetics encompasses all processes that determine how a substance is absorbed after ingestion, distributed throughout the body, biochemically transformed, and ultimately eliminated. These processes are commonly summarized by the acronym ADME: Absorption, Distribution, Metabolism, and Excretion.

Absorption

Ubiquinol is a highly lipophilic (fat-soluble) compound, meaning its intestinal absorption is strongly dependent on the co-ingestion of dietary fat. Absorption occurs primarily in the small intestine, where ubiquinol is incorporated into micelles and taken up through the intestinal wall into the lymphatic system. Research demonstrates that ubiquinol has a significantly higher bioavailability compared to its oxidized counterpart ubiquinone, as it does not require an enzymatic reduction step before use.

Co-administration with a fat-containing meal significantly enhances absorption.
Bioavailability varies depending on the formulation (e.g., solubility-enhanced softgel capsules).
In the bloodstream, ubiquinol is primarily transported bound to lipoproteins, particularly LDL and HDL.

Distribution

Following intestinal absorption, ubiquinol enters the bloodstream via the lymphatic system and is distributed to various tissues. The highest concentrations are found in organs with high energy demands, including:

Cardiac muscle tissue
Liver
Kidneys
Skeletal muscle
Brain

In blood plasma, approximately 90–95% of total Coenzyme Q10 exists in the reduced ubiquinol form. This ratio is considered a biomarker for the body's oxidative stress status. A lower ubiquinol-to-ubiquinone ratio may indicate elevated oxidative stress.

Metabolism

Ubiquinol undergoes a dynamic interconversion with its oxidized form, ubiquinone. This conversion is reversible and regulated by various enzymes:

Oxidation: Ubiquinol donates electrons and is converted to ubiquinone – a central step in the mitochondrial respiratory chain.
Reduction: Ubiquinone can be reduced back to ubiquinol by enzymes such as NADH-dependent reductases.

Metabolism occurs primarily in the liver, where CoQ10 is also endogenously synthesized. Endogenous ubiquinol synthesis declines with advancing age, making supplementation particularly relevant for older individuals.

Excretion

Ubiquinol is excreted predominantly via bile and feces. Renal (urinary) excretion plays a minor role due to the compound's strong lipophilicity. The plasma half-life of ubiquinol ranges from approximately 33 to 48 hours across studies, supporting once- or twice-daily dosing regimens from a pharmacokinetic standpoint.

Clinical Relevance of Ubiquinol Biokinetics

Understanding the biokinetics of ubiquinol is clinically significant in several areas:

Heart failure: Studies such as the Q-SYMBIO trial demonstrate that ubiquinol supplementation can improve cardiac function in patients with chronic heart failure.
Statin therapy: Statins inhibit endogenous CoQ10 synthesis by blocking the mevalonate pathway. Ubiquinol supplementation may counteract this effect.
Oxidative stress: As a potent antioxidant, ubiquinol protects cell membranes and lipoproteins from oxidative damage.
Mitochondrial disorders: In cases of genetic mitochondrial dysfunction, high-dose ubiquinol administration may have therapeutic value.

Factors Influencing Biokinetics

Several factors affect the individual pharmacokinetics of ubiquinol:

Age: Intestinal absorption capacity and endogenous synthesis both decline with age.
Formulation: Solubility-optimized delivery systems (e.g., self-emulsifying systems) markedly increase bioavailability.
Concomitant medications: Statins and other drugs can influence plasma CoQ10 levels.
Underlying disease: Chronic conditions, particularly of the liver and heart, alter the distribution and metabolism of ubiquinol.
Dietary fat intake: Fat-rich meals significantly enhance absorption.

References

Bhagavan, H.N. & Chopra, R.K. (2006): Coenzyme Q10: Absorption, tissue uptake, metabolism and pharmacokinetics. In: Free Radical Research, 40(5), 445–453.
Hosoe, K. et al. (2007): Study on safety and bioavailability of ubiquinol (Kaneka QH) after single and 4-week multiple oral administration to healthy volunteers. In: Regulatory Toxicology and Pharmacology, 47(1), 19–28.
Mortensen, S.A. et al. (2014): The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. In: JACC Heart Failure, 2(6), 641–649.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.